Want to see HK:2170 full AI Analyst Report?
Suzhou Basecare Medical Corp. Ltd. Class H (2170) AI Stock Analysis
Top Page
Suzhou Basecare Medical Corp. Ltd. Class H
(HKEX:2170)
The score is primarily held back by weak financial performance—large ongoing losses, persistent negative operating/free cash flow, and a notable 2025 revenue decline. Technicals add further pressure with a multi-timeframe downtrend and bearish momentum. Valuation provides only limited offset because the negative P/E reflects unprofitability and no dividend yield is available.
Suzhou Basecare Medical Corp. Ltd. Class H (2170) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 379.92M
- Dividend Yield
- ―
- Average Volume (3M)
- 60.02K
- Price to Earnings (P/E)
- -1.8
- Beta (1Y)
- 0.62
- Revenue Growth
- -2.28%
- EPS Growth
- 24.76%
- Country
- Hong Kong
- Employees
- 388
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Suzhou Basecare Medical Corp. Ltd. Class H Business Overview & Revenue Model
Company Description
Suzhou Basecare Medical Corporation Limited, an investment holding company established in Suzhou, China, in 2010, focuses its business activities within the People's Republic of China. The company primarily engages in the research, development, and m...
How the Company Makes Money
The company makes money primarily by selling medical devices and consumable products used in assisted reproduction and fertility treatment workflows (e.g., IVF-related devices and supporting consumables) to institutional healthcare customers such as...
Suzhou Basecare Medical Corp. Ltd. Class H Financial Statement Overview
Summary
Despite solid gross margin (~48% in 2025) and a not-overlevered balance sheet (debt-to-equity ~0.37), fundamentals are constrained by a sharp 2025 revenue decline (-17.6% YoY), very large operating and net losses (EBIT margin ~-88%, net margin ~-96%), and persistent cash burn (operating cash flow ~-160M; free cash flow ~-243M in 2025).
Income Statement
28NegativeBalance Sheet
62PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 260.68M | 233.27M | 299.11M | 207.98M | 140.90M | 107.30M |
| Gross Profit | 139.75M | 123.61M | 136.22M | 91.35M | 59.53M | 51.15M |
| EBITDA | -100.14M | -162.43M | -232.10M | -174.14M | -117.73M | -118.88M |
| Net Income | -174.03M | -223.46M | -237.03M | -191.69M | -123.16M | -143.65M |
Balance Sheet | ||||||
| Total Assets | 1.33B | 1.45B | 1.67B | 1.90B | 1.78B | 1.80B |
| Cash, Cash Equivalents and Short-Term Investments | 378.43M | 447.34M | 684.63M | 945.71M | 1.33B | 1.52B |
| Total Debt | 342.35M | 343.51M | 328.42M | 281.92M | 75.54M | 48.57M |
| Total Liabilities | 468.21M | 512.00M | 527.47M | 499.98M | 188.33M | 85.85M |
| Stockholders Equity | 864.78M | 935.06M | 1.14B | 1.40B | 1.59B | 1.72B |
Cash Flow | ||||||
| Free Cash Flow | -132.51M | -243.37M | -322.41M | -371.44M | -317.52M | -234.71M |
| Operating Cash Flow | -97.88M | -160.01M | -229.12M | -267.23M | -188.77M | -197.85M |
| Investing Cash Flow | -44.37M | -5.33M | -181.19M | -324.81M | -88.70M | -56.60M |
| Financing Cash Flow | -1.77M | 16.13M | 33.78M | 190.55M | 23.51M | 1.60B |
Suzhou Basecare Medical Corp. Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2170, the sentiment is Positive. The current price of 1.37 is above the 20-day moving average (MA) of 1.31, above the 50-day MA of 1.33, and below the 200-day MA of 1.62, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 57.16 is Neutral, neither overbought nor oversold. The STOCH value of 67.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2170.
Suzhou Basecare Medical Corp. Ltd. Class H Peers Comparison
Overall Rating
HK:178972Outperform
HK:130256Neutral- HK:217044Neutral
HK:250044Neutral
HK:216043Neutral
HK:085341Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1789 | 72Outperform | HKD 5.05B | 11.38 | 13.24% | 2.59% | 16.15% | 31.89% |
| HK:1302 | 56Neutral | HKD 6.35B | 98.22 | 1.71% | ― | 0.75% | -20.22% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2170 | 44Neutral | HKD 374.73M | -1.83 | -19.34% | ― | -2.28% | 24.76% |
| HK:2500 | 44Neutral | HKD 432.19M | -0.78 | -28.24% | ― | -38.15% | 25.70% |
| HK:2160 | 43Neutral | HKD 1.63B | -0.86 | -6.69% | ― | ― | ― |
| HK:0853 | 41Neutral | HKD 11.65B | 31.23 | 6.07% | ― | -3.62% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2170 | Suzhou Basecare Medical Corp. Ltd. Class H | 1.37 | -1.16 | -45.85% | |
| HK:0853 | MicroPort Scientific Corp | 6.08 | -5.92 | -49.33% | |
| HK:1302 | LifeTech Scientific Corporation | 1.47 | -0.58 | -28.29% | |
| HK:1789 | AK Medical Holdings Ltd. | 4.56 | -1.34 | -22.75% | |
| HK:2160 | MicroPort CardioFlow Medtech Corp. | 1.28 | -4.67 | -78.49% | |
| HK:2500 | Venus Medtech (Hangzhou), Inc. Class H | 0.98 | -1.77 | -64.36% |
Suzhou Basecare Medical Corp. Ltd. Class H Corporate Events
Suzhou Basecare Launches RMB5 Million Share Buy-Back to Boost Investor Value
Suzhou Basecare Medical Corporation Limited has received shareholder approval to repurchase up to 10% of its H shares, equivalent to 8,271,383 shares, under a general repurchase mandate granted at its 2025 annual general meeting. The repurchases, whi...
Basecare Wins NMPA Nod for New Embryo Cryopreservation Reagents
Suzhou Basecare Medical Corporation Limited has received National Medical Products Administration approval for Class III medical device registration certificates for its Gems Vitrification Set and Warming Set, key reagents used in embryo cryopreserva...
Suzhou Basecare Narrows Losses and Secures Landmark PGT Approvals in China
Suzhou Basecare Medical Corporation Limited reported interim unaudited results for the six months ended 30 June 2026, with revenue rising 27.0% year on year to RMB128.7 million and losses narrowing significantly, as loss attributable to shareholders...
Suzhou Basecare Board to Review Interim Results and Possible Dividend
Suzhou Basecare Medical Corporation Limited, a Hong Kong-listed healthcare company based in Suzhou, operates through a group structure that includes several subsidiaries and is governed by a board made up of executive, non-executive and independent n...
Suzhou Basecare Cuts Losses as Genetic Testing and Culture Media Drive Revenue Surge
Suzhou Basecare Medical Corporation Limited expects significant improvement in its interim 2026 results, with revenue projected to rise to about RMB125.7 million to RMB130.8 million, a 24% to 29% increase year-on-year. The loss attributable to equity...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026